Apellis Pharmaceuticals Inc (NASDAQ:APLS) CEO Cedric Francois sold 5,000 shares of the firm’s stock in a transaction dated Monday, September 16th. The shares were sold at an average price of $26.59, for a total transaction of $132,950.00.

Cedric Francois also recently made the following trade(s):

  • On Thursday, August 15th, Cedric Francois sold 10,000 shares of Apellis Pharmaceuticals stock. The shares were sold at an average price of $26.80, for a total transaction of $268,000.00.

APLS stock traded up $0.39 during mid-day trading on Thursday, hitting $26.64. 20,394 shares of the company were exchanged, compared to its average volume of 548,110. The business has a 50 day simple moving average of $28.52 and a 200-day simple moving average of $23.02. The company has a current ratio of 8.67, a quick ratio of 8.67 and a debt-to-equity ratio of 0.08. The stock has a market capitalization of $1.67 billion, a PE ratio of -11.42 and a beta of 0.74. Apellis Pharmaceuticals Inc has a 1-year low of $11.45 and a 1-year high of $33.18.

Apellis Pharmaceuticals (NASDAQ:APLS) last announced its earnings results on Wednesday, July 31st. The company reported ($0.98) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.80) by ($0.18). Equities research analysts expect that Apellis Pharmaceuticals Inc will post -3.9 earnings per share for the current year.

Several institutional investors and hedge funds have recently made changes to their positions in the company. Ladenburg Thalmann Financial Services Inc. increased its holdings in shares of Apellis Pharmaceuticals by 160.0% during the second quarter. Ladenburg Thalmann Financial Services Inc. now owns 1,300 shares of the company’s stock worth $33,000 after purchasing an additional 800 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in shares of Apellis Pharmaceuticals by 59.6% during the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,944 shares of the company’s stock worth $75,000 after purchasing an additional 1,099 shares during the period. Tower Research Capital LLC TRC bought a new position in shares of Apellis Pharmaceuticals during the second quarter worth approximately $39,000. Swiss National Bank increased its holdings in shares of Apellis Pharmaceuticals by 2.1% during the second quarter. Swiss National Bank now owns 81,100 shares of the company’s stock worth $2,055,000 after purchasing an additional 1,700 shares during the period. Finally, Bailard Inc. increased its holdings in shares of Apellis Pharmaceuticals by 15.4% during the second quarter. Bailard Inc. now owns 15,000 shares of the company’s stock worth $380,000 after purchasing an additional 2,000 shares during the period. 63.44% of the stock is currently owned by institutional investors.

Several equities research analysts recently issued reports on the stock. Zacks Investment Research downgraded shares of Apellis Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Tuesday, July 16th. Oppenheimer initiated coverage on shares of Apellis Pharmaceuticals in a research report on Tuesday, July 9th. They set an “outperform” rating and a $52.00 price objective for the company. Cantor Fitzgerald restated an “overweight” rating and set a $50.00 price objective (down from $52.00) on shares of Apellis Pharmaceuticals in a research report on Thursday, August 1st. ValuEngine downgraded shares of Apellis Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday, August 1st. Finally, JPMorgan Chase & Co. upgraded shares of Apellis Pharmaceuticals from a “neutral” rating to an “overweight” rating and raised their price objective for the stock from $35.00 to $49.00 in a research report on Friday, July 12th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and seven have issued a buy rating to the company’s stock. Apellis Pharmaceuticals currently has an average rating of “Buy” and a consensus price target of $45.14.

Apellis Pharmaceuticals Company Profile

Apellis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. Its lead product candidate is APL-2 that is in Phase III clinical trials for the treatment of geographic atrophy in age-related macular degeneration and paroxysmal nocturnal hemoglobinuria diseases; and in Phase II clinical trials for the treatment of cold agglutinin and warm antibody autoimmune hemolytic anemia diseases, as well as in Phase II clinical trials to treat four types of glomerular diseases, such as C3 glomerulopathy, IgA nephropathy, primary membranous nephropathy, and lupus nephritis.

Featured Article: Understanding debt-to-equity ratio in fundamental analysis

Receive News & Ratings for Apellis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apellis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.